Once a year, many worldwide leaders in the treatment of Alzheimer’s disease meet at the Clinical Trials on Alzheimer’s Disease (CTAD) conference to discuss new results, candidate therapeutics and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

This year, the 11th Clinical Trials on Alzheimer’s Disease conference took place from 24 to 27 October in Barcelona. Delegates from worldwide centers reported on their work and efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for Alzheimer’s disease, to predict progression, and assess the effectiveness of new treatments.

It was a huge delight for some AMYPAD members to spend the few days in Barcelona to discuss science and to present the AMYPAD project. On 26 October, our project coordinator Professor Frederik Barkhof (VU university medical center, VUmc, The Netherlands) gave an oral presentation on behalf of the AMYPAD consortium entitled “Development of an Amyloid Staging Model: Associations with Clinical Measures”. We are also pleased that Gemma Salvadó from BarcelonaβetaBrain Research Center (BBRC, Spain) presented an AMYPAD poster titled “Supratentorial white matter appears to be a better reference region than standard infratentorial regions for longitudinal quantification of [18F]flutemetamol scans” and got a lot of attention.

To access the conference website, please visit http://www.ctad-alzheimer.com/

Mark your agenda for CTAD 2019!
12th Clinical Trials on Alzheimer’s Disease (CTAD)
December 4-7, 2019 – San Diego, USA